Equities

Verona Pharma PLC

Verona Pharma PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)29.43
  • Today's Change0.20 / 0.68%
  • Shares traded645.43k
  • 1 Year change+70.76%
  • Beta0.4344
Data delayed at least 15 minutes, as of Sep 19 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments272228148
Total Receivables, Net119.2816
Total Inventory------
Prepaid expenses3.622.504.04
Other current assets, total3.373.392.06
Total current assets290243170
Property, plant & equipment, net2.870.930.98
Goodwill, net0.550.550.55
Intangibles, net------
Long term investments151515
Note receivable - long term------
Other long term assets------
Total assets308259187
LIABILITIES
Accounts payable3.492.9110
Accrued expenses4.771423
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total0.441.690.47
Total current liabilities8.691933
Total long term debt489.774.87
Total debt489.774.87
Deferred income tax------
Minority interest------
Other liabilities, total1.780.210.29
Total liabilities592939
SHAREHOLDERS EQUITY
Common stock434132
Additional paid-in capital601529385
Retained earnings (accumulated deficit)(388)(333)(264)
Treasury stock - common(1.52)(1.55)(0.6)
Unrealized gain (loss)------
Other equity, total(4.6)(4.6)(4.6)
Total equity249230148
Total liabilities & shareholders' equity308259187
Total common shares outstanding644606480
Treasury shares - common primary issue------
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.